$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
The ovary is a dynamic, endocrinologically active organ, consisting of an outer cortex and an inner medulla. Heterogeneously distributed within the ovaries are follicles, which contain the gonadal oocyte surrounded by stromal granulosa cells1. All follicles are already formed during fetal development, peaking at around 20 weeks of gestational age, followed by an exponential decline. At birth, 1-2 million primordial follicles remain within the cortex, and only a few hundred thousand follicles survive until puberty2. The non-growing follicle pool, also referred to as the ovarian reserve, influences a woman's fertility, among other factors. The ovarian reserve resides within the cortex and moves into the medulla as the follicles grow and mature. Some researchers recognize the ovarian reserve as being comprised of primordial follicles only, while others include all unilaminar follicles (i.e., primordial, intermediary, and primary)3,4,5,6. During a woman's lifetime, only 300-400 follicles mature and survive to eventually undergo ovulation. Menopause commences when the follicle number drops to around a thousand, which typically occurs at around 50 years of age2,7. There is currently an ongoing debate regarding the presence of oogonial stem cells (OSCs) in adult human ovaries that can form oocytes after xenotransplantation. Some studies suggest isolating cells that express a gene profile of primitive germ cells and differentiate into oocytes8,9, while others indicate that the alleged OSCs are perivascular cells of the blood vessels10,11,12.
Premature ovarian insufficiency (POI) is defined by the discontinuation of the menstrual cycle with raised FSH levels before the age of 40 years13. The causes of POI are multifactorial and can occur idiopathically; however, it often arises as a result of medical conditions14. For example, certain congenital genetic conditions are associated with POI due to a reduced ovarian reserve already at birth, such as Turner's syndrome15. POI can also occur as a side effect of gonadotoxic treatments, which is particularly problematic in very young patients as it may lead to an inability to undergo normal puberty and drastically impair the ovarian reserve. Depending on the risk of POI and the patient's age, several fertility preservation options are available, such as cryopreservation of mature oocytes, cryopreservation of embryos after in vitro fertilization, and ovarian tissue cryopreservation (OTC). For pre-pubertal patients, OTC is the only feasible option due to their sexual immaturity16,17. In the United States, fertility preservation through OTC has recently been considered an acceptable clinical routine18. However, OTC is still considered experimental in many European countries, and ethical approval is required, particularly for auto-transplantation19,20. Therefore, inclusion criteria for OTC protocols must be carefully considered, and a risk-benefit analysis should be performed for each patient. Not all children receiving gonadotoxic therapies are eligible for fertility preservation. In Sweden, only patients with high or very high risk are recommended to undergo fertility preservation in accordance with the guidelines on fertility preservation of the Nordic Society of Paediatric Haematology and Oncology21. This group includes (1) pre- and post-pubertal children requiring stem cell transplantation or receiving radiation therapy with the ovary in the field of range, and (2) post-pubertal children with high cumulative doses of alkylating chemotherapy. For girls before menarche, inclusion criteria for very high risk of infertility include those treated with any of the following: radiation dose >10 Gy to the ovary, or allogeneic or autologous hematopoietic stem cell therapy (HSCT). Exclusion criteria include those who need additional blood products for other anticoagulant preparations before surgery or have a neutrophil count <1. For girls/women after menarche, inclusion criteria for high or very high risk of infertility include those treated with any of the following: radiation dose >10 Gy to the ovary, or allogeneic HSCT, cyclophosphamide >9 g/m², ifosfamide >60 g/m², procarbazine, or nitrosourea compounds (BCNU/CCNU) >360 mg/m². Exclusion criteria include those with an increased risk of bleeding, increased risk of infection, increased risk of surgical complications, or increased risk of pain problems as assessed by the physician in charge.
For OTC, ovarian tissue is collected during abdominal surgeries by laparotomy or laparoscopy through unilateral oophorectomy or biopsy. The medulla is removed from the collected ovarian tissue, and the remaining cortex is then sectioned into smaller fragments for cryopreservation through controlled-rate freezing or vitrification for later use in fertility restoration22. The samples are then stored in liquid nitrogen until the patient recovers from her treatment and wishes to start a family. Depending on the type of cancer and in the absence of contraindications to ovarian tissue transplantation, the tissue is then thawed and autografted to restore hormonal and ovarian function. OTC has been proven successful, with a 50% pregnancy rate and more than 200 live births reported after grafting of cryopreserved ovarian tissue collected during adulthood23,24,25. Reported live births after auto-transplantation of ovarian tissue collected during childhood are few, and none have been reported after auto-transplantation of undoubtedly pre-pubertal ovarian tissue26,27,28,29,30. Tissue quality is a prerequisite for successful fertility restoration31. Therefore, it is essential to study the quality of the collected tissue samples.
Currently, a way of estimating the quality of the ovarian tissue is through histological sections and manual counting of the follicles. However, assessing the normality of follicle density is difficult due to the natural decline of the reserve with increasing age and the heterogeneous distribution of follicles. Additionally, comparison to reference values is challenging as they are not standardized for biopsy size and age. Other assessment options, such as AMH serum levels or staining of digested tissue with calcein or neutral red, are either not well established or come with their own limitations. Wallace and Kelsey previously published a model of normal ovarian reserve over age by collecting data on follicle numbers from whole ovaries of patients with no known ovarian pathologies2. Furthermore, as biopsies are not representative of the whole ovary, Schmidt et al. developed a method for estimating the total number of follicles based on cortical biopsies32. Using a modified version of this method and the model of normal ovarian reserve, a reference dataset for follicle density of women aged 0-25 years was established33.
This article describes the strategy for assessing the normality of follicle density based on small ovarian samples by (1) direct quantification of the follicles using histology and (2) comparison of the results to age-normalized standard references via Z-scores. The use of Z-scores describes the relationship of an ovarian biopy's follicle density to an age- and size-standardized reference group mean. This will be of great value for physicians in counseling their patients for auto-transplantation and further treatment after fertility preservation.